Literature DB >> 25727220

Aggressive repeat surgery for focally recurrent primary glioblastoma: outcomes and theoretical framework.

Michael E Sughrue1, Tyson Sheean, Phillip A Bonney, Adrian J Maurer, Charles Teo.   

Abstract

OBJECT The relative benefit of repeat surgery for recurrent glioblastoma is unclear, in part due to the very heterogeneous nature of the patient population and the effect of clinician philosophy on the duration and aggressiveness of treatment. The authors sought to investigate the role of time to last recurrence on patient outcomes following aggressive repeat surgery for recurrent glioblastoma. METHODS The authors present outcomes in 104 patients undergoing repeat surgery for focally recurrent glioblastoma with at least 95% resection and adjuvant treatment at most recent prior surgery. In addition to common variables, they provide data regarding the period of progression-free survival (PFS) following an aggressive lesionectomy for focally recurrent primary glioblastoma (T2) and the time the tumor took to recur since the previous surgery (T1). They term the ratio T1/T2 the relative aggressivity index (RAI). RESULTS The median PFS was 7.8 months, 6.0 months, and 4.8 months following the second, third, and fourth-sixth craniotomies, respectively. Importantly, there was a wide range of outcomes, with time to postoperative recurrence ranging from 1 to 24 months in this group. Analysis showed no meaningful relationship between T1 and T2, meaning that previous PFS is entirely unable to predict the PFS that another surgery will provide the patient. CONCLUSIONS Repeat surgery for glioblastoma is beneficial in many cases, however this is hard to predict preoperatively. Often, surgery can provide the patient with a good period of disease freedom, but this is variable and in general it is not possible to reliably predict who these patients are.

Entities:  

Keywords:  GBM; GBM = glioblastoma; KPS = Karnofsky Performance Status; OS = overall survival; PFS = progression-free survival; RAI = relative aggressivity index (T1/T2 ratio); RANO = Response Assessment in Neuro-Oncology; T1 = time from previous surgery to GBM recurrence; T2 = period of progression-free survival following an aggressive lesionectomy for focally recurrent primary GBM; astrocytoma; glioblastoma; recurrence; recurrent glioma; surgery; survival

Mesh:

Year:  2015        PMID: 25727220     DOI: 10.3171/2014.12.FOCUS14726

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  18 in total

1.  Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.

Authors:  Christoph Straube; Greeshma Elpula; Jens Gempt; Julia Gerhardt; Stefanie Bette; Claus Zimmer; Friederike Schmidt-Graf; Bernhard Meyer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-06-14       Impact factor: 3.621

2.  Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Authors:  David Botros; Hayden Dux; Carrie Price; Adham M Khalafallah; Debraj Mukherjee
Journal:  Neurosurg Rev       Date:  2020-06-13       Impact factor: 3.042

3.  Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit.

Authors:  Mateo Tomas Fariña Nuñez; Pamela Franco; Debora Cipriani; Nicolas Neidert; Simon P Behringer; Irina Mader; Daniel Delev; Christian Fung; Jürgen Beck; Roman Sankowski; Nils Henrik Nicolay; Dieter Henrik Heiland; Oliver Schnell
Journal:  J Neurooncol       Date:  2020-01-13       Impact factor: 4.130

4.  Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Authors:  Cecilia L Dalle Ore; Ankush Chandra; Jonathan Rick; Darryl Lau; Maryam Shahin; Alan T Nguyen; Michael McDermott; Mitchel S Berger; Manish K Aghi
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

Review 5.  A Second Course of Radiotherapy in Patients with Recurrent Malignant Gliomas: Clinical Data on Re-irradiation, Prognostic Factors, and Usefulness of Digital Biomarkers.

Authors:  Christoph Straube; Kerstin A Kessel; Claus Zimmer; Friederike Schmidt-Graf; Jürgen Schlegel; Jens Gempt; Bernhard Meyer; Stephanie E Combs
Journal:  Curr Treat Options Oncol       Date:  2019-07-19

6.  Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults.

Authors:  Mateo Ziu; Sharad Goyal; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2021-11-08       Impact factor: 4.130

Review 7.  Temozolomide-associated hypermutation in gliomas.

Authors:  Serah Choi; Yao Yu; Matthew R Grimmer; Michael Wahl; Susan M Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

8.  Reliability of Semi-Automated Segmentations in Glioblastoma.

Authors:  T Huber; G Alber; S Bette; T Boeckh-Behrens; J Gempt; F Ringel; E Alberts; C Zimmer; J S Bauer
Journal:  Clin Neuroradiol       Date:  2015-10-21       Impact factor: 3.649

9.  Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma.

Authors:  Stephen J Bagley; Robert D Schwab; Ernest Nelson; Angela N Viaene; Zev A Binder; Robert A Lustig; Donald M O'Rourke; Steven Brem; Arati S Desai; MacLean P Nasrallah
Journal:  J Neurooncol       Date:  2018-11-16       Impact factor: 4.130

10.  Symptom resolution in infiltrating WHO grade II-IV glioma patients undergoing surgical resection.

Authors:  Joshua D Burks; Phillip A Bonney; Chad A Glenn; Andrew K Conner; Robert G Briggs; Peter A Ebeling; Lucas C Toho; Michael E Sughrue
Journal:  J Clin Neurosci       Date:  2016-07-06       Impact factor: 2.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.